<DOC>
	<DOCNO>NCT01008527</DOCNO>
	<brief_summary>The purpose study determine side effect CP 870,893 may cause give immune stimulant call Oncovir poly IC : LC along melanoma vaccine . The CP 870,893 , Oncovir poly IC : LC melanoma vaccine investigational drug combine patient , approve sale Food Drug Administration . The Oncovir poly IC : LC intend stimulate body 's immune system .</brief_summary>
	<brief_title>Phase I Oncovir Poly IC : LC NY-ESO-1/gp100</brief_title>
	<detailed_description>Antibodies CP 870,893 chemical make immune cell naturally find human body . CP 870,893 produce cell grown hamster fully human composition . The vaccine contain peptide ( piece ) two different protein call NY-ESO-1 gp100 . Each one make 50-100 % melanoma . These protein recognize immune system . They inject skin participant 's thigh combination , without oil-based substance , call `` Montanide ISA 51 VG '' . The Montanide ISA 51 VG adjuvant `` assistant '' stimulate body 's immune system . The peptide vaccine , Montanide ISA 51 VG , Oncovir poly IC : LC CP 870,893 antibody approve Food Drug Administration ( FDA ) FDA permit use study . It believe CP 870,893 Oncovir poly IC : LC boost body 's immune response melanoma vaccine , although vaccine prove help patient 's melanoma .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Poly I-C</mesh_term>
	<criteria>Patients must meet follow criterion prestudy examination ( within 28 day prior study drug administration ) eligible participate study : Have read , understood , provide write informed consent Health Insurance Portability Accountability Act ( HIPAA ) authorization nature study fully explain Histologic diagnosis Stage III ( ≥ 3 positive lymph node ) Stage IV melanoma resect completely ( may include mucosal ocular melanoma ) 6 month prior screen Human leukocyte antigen ( HLA ) A*0201 status determine deoxyribonucleic acid ( DNA ) allelespecific polymerase chain reaction ( PCR ) assay Positive stain tumor tissue least one following : antibody HMB45 gplOO , NYESOl , MARTI At least 4 week since treatment ( surgery , chemotherapy , immunotherapy , radiotherapy ) least 6 week treatment nitrosoureas melanoma , least 8 week since adjuvant treatment anticytotoxic Tlymphocyteassociated antigen4 ( CTLA4 ) antibody melanoma recover serious toxicity experience treatment Women must either : postmenopausal least 1 year ; surgically incapable bearing child ; utilize reliable form contraception study least 4 month final CP 870,893 infusion vaccination . Women childbearing potential must negative serum hCG ß pregnancy test conduct screening period negative urine pregnancy test conduct day infusion ( prior infusion ) . Men may father child must agree use male contraception duration participation trial least 4 month final CP 870,893 infusion vaccination . Patients Stage III resect melanoma render free disease fail treatment , ineligible , refuse treatment ainterferon . Analgesic therapy must stable period 14 day prior infusion study drug . Life expectancy ≥ 6 month Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Patients resect brain metastasis steroid , evidence disease brain magnetic resonance imaging ( MRI ) scanning , computer tomography ( CT ) brain MRI perform , eligible . Screening laboratory value must meet following criterion : white blood cell ( WBC ) : ≥2500 cells/mm³ ; absolute neutrophil count ( ANC ) : ≥1500 cells/mm³ , Platelets : ≥100,000/mm³ ; Hematocrit : ≥30 % ; Hemoglobin : ≥10 g/dL ; Creatinine : ≤2.0 mg/dL ; aspartate aminotransferase ( AST ) : ≤3 x ULN ; Bilirubin : ≤1.0 x upper limit normal ( ULN ) ( except patient Gilbert 's Syndrome must total bilirubin less 3.0 mg/dL ) ; human immunodeficiency virus ( HIV ) : negative ; HBsAg : negative ; hepatitis C virus ( HCV ) antibody [ antiHCV Ab ] : nonreactive . If reactive , patient must negative HCV RNA qualitative PCR . Any prior malignancy except follow : adequately treat basal squamous cell skin cancer , superficial bladder cancer , carcinoma situ cervix , cancer patient diseasefree least 5 year . History autoimmune disease , specifically include follow disease : inflammatory bowel disease autoimmune bowel disease ; systemic lupus erythematosis ; rheumatoid arthritis ; autoimmune ocular disease . Patients autoimmune disease history affect pancreas , pituitary , liver , gastrointestinal ( GI ) tract adrenal , prior history GuillanBarre neurologic condition felt autoimmune nature also exclude . Active infection , require therapy , chronic active hepatitis B virus ( HBV ) HCV , confirm reactivity HIV test . Pregnancy nursing : due possibility CP 870,893 could detrimental effect develop immune system fetus infant , exposure utero via breast milk allow . Systemic hypersensitivity Montanide ISA 51 ( IFA ) , Montanide ISA 51 VG vaccine component Any underlying medical condition , opinion Principal Investigator ( PI ) , make administration study drug hazardous obscure interpretation adverse event . Any concurrent medical condition require use systemic , inhaled topical corticosteroid use immunosuppressive agent ( e.g . cyclosporine analog , chemotherapy agent ) . All corticosteroid use must discontinue least 4 week prior study entry . Prior treatment CP 870,893 antiCD40 antibody Evidence history significant cardiac , pulmonary , hepatic , renal , psychiatric gastrointestinal disease would make administration CP 870,893 unsafe Concurrent treatment chemotherapy immunotherapy regimen ( must complete least 4 week Screening ; 6 week nitrosoureas ) ; prior treatment chemotherapy , radiotherapy anti CD40 antibodies exclusion . History prior allogeneic human stem cell bone marrow transplant History prior thromboembolic venous event , inherit / acquire coagulopathies</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>skin</keyword>
	<keyword>cutaneous</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>immunology</keyword>
	<keyword>dose escalation</keyword>
</DOC>